501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Makes
Significant Breakthrough in FAIMS Technology
Development
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- March
2, 2020
--
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer of
marijuana breathalyzer devices for law enforcement and the
workplace reports that
a
significant
technological development has been achieved with its
FAIMS-
(field asymmetric waveform ion mobility spectrometry)
marijuana
breathalyzer prototype.
Cannabix scientists
have been characterizing the device for several months to
increase resolving power and
sensitivity. The Company is
pleased to report that the Beta 3.1 FAIMS
device
has
achieved
ion-resolving
levels that
enable
the isolation of ?9-tetrahydrocannabinol
("THC") in human
breath and suppress
background compounds
effectively.
With
human subject breath testing
performed
up to
90 minutes after smoking marijuana and nicotine
cigarettes, the
Cannabix FAIMS
device
was
able to selectively
isolate
THC
or
nicotine
and
supress unwanted background
volatile organic
compounds. In addition,
metabolites for both cannabis and nicotine were
detected. Subject testing up
to 90 minutes after
smoking was
accomplished
using
only a
few breath
samples
from the test subject.
The
characterization work and recent developments were
conducted using a
bench version of the Beta 3.1 FAIMS device coupled to
mass spectrometer for
validation. A number of factors
including FAIMS cell geometry, flow optimization and ion-focusing
techniques have contributed to this latest development.
"I'm
impressed with the progress that has been made by the Cannabix team
in the development of this newest version; the sensitivity and
selectivity is impressive. I look forward to continued
collaborations between UF and Cannabix to advance FAIMS
detection." says Dr. Richard
Yost, Cannabix Scientific Advisor.
"We
are very excited about our recent results on being able to
consistently resolve THC and other analytes from
breath.
It is hard to
overstate the significance
of
these
achievements
in atmospheric
conditions (without vacuum). These key steps
will result in a new type of device that the analytical and
diagnostic fields have been seeking for breath
analysis." says Dr.
Raj Attariwala, Chief
Scientific Officer
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable tools to market to enhance detection of marijuana impaired
driving offences on roads at a time when marijuana is becoming
legal in many global jurisdictions. Cannabix is working to develop
drug-testing devices that will detect THC- the psychoactive
component of marijuana that causes intoxication- using breath
samples. In particular,
Cannabix is focused on developing breath testing devices for
detection of recent use of THC, in contrast to urine testing for
THC metabolite that requires an invasive collection and reflects
usage,
days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment
by THC
can be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.